Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)

The National Institutes of Health (NIH) is reissuing the Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access program under the X01 activity code. This program facilitates access to CIDR’s advanced genetic and genomic analysis services for NIH-supported projects without providing direct funding. CIDR’s high-throughput services support gene discovery, characterization of genetic variations, and genotyping, all of which aid in identifying genetic factors contributing to human health and disease. These services are especially useful for studies that involve extensive specimen collections with associated clinical and phenotypic data, where the integration of high-quality genotype or sequence data can enhance research value and contribute to the broader scientific community. The CIDR resources are administered by the National Human Genome Research Institute (NHGRI), and program details, including specific CIDR services, are available at the CIDR website. This NOFO is geared toward projects that focus on identifying genetic or epigenetic factors in human health or adding genetic data to well-characterized specimen collections, enabling further phenotypic or stratification analysis. Projects must demonstrate strong evidence of a genetic component to the trait under study or show that the addition of high-throughput data will substantively enhance an existing research collection. Studies may utilize CIDR’s next-generation sequencing, genome-wide association studies (GWAS), custom SNP genotyping, or DNA methylation analysis, with a focus primarily on human data, though some model organism studies may qualify. Successful applicants will receive access to CIDR’s services rather than funds. Applicants with linked active research grants are encouraged to use those funds for associated project costs, including sample handling, statistical analysis, and data management. For those without linked active NIH grants, applicants may seek alternative funding (such as a small research grant or administrative supplement) for these ancillary activities. Applications must include a comprehensive data-sharing plan that facilitates broad dissemination of data, including covariate and genotype information through NIH-approved repositories. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofit organizations, government entities, and both domestic and non-U.S. institutions. Applications must be linked to an NIH research grant and require written permission from a participating NIH Institute. Applicants are advised to seek this permission approximately four to six months before submission. Application content should include specific aims, a study population description, sample details, power calculations, data analysis plans, and follow-up study proposals. Additionally, data sharing with the NIH Genomic Data Repository (such as dbGaP) is mandatory for access to CIDR services. The review process will emphasize the scientific merit and significance of the proposed work, particularly the potential to address significant genetic and epigenetic research questions, the strength of the supporting data, the qualifications of the investigators, and the suitability of the study design and sample size. Applications are subject to NIH’s peer review process, with reviews occurring approximately 120 days after submission. Key review criteria include the potential public health impact of the research, the robustness of the genetic models and statistical methods, and plans for subsequent phases of research. The CIDR program offers a unique opportunity for research projects requiring specialized genotyping and sequencing support without incurring the costs of directly acquiring these services. It aims to advance the field of genetic and epigenetic research through the provision of resources that may be difficult for individual investigators to access independently. Applications are accepted on a rolling basis until the expiration date of July 9, 2026, and applicants are encouraged to apply early to address any submission issues.